Literature DB >> 18930804

Development of glycopeptide-intermediate resistance by Staphylococcus aureus leads to attenuated infectivity in a rat model of endocarditis.

Paul A Majcherczyk1, Jean-Luc Barblan, Philippe Moreillon, José M Entenza.   

Abstract

Glycopeptide-intermediate resistant Staphylococcus aureus (GISA) are characterized by multiple changes in the cell wall and an altered expression of global virulence regulators. We investigated whether GISA are affected in their infectivity in a rat model of experimental endocarditis. The glycopeptide-susceptible, methicillin-resistant S. aureus M1V2 and its laboratory-derived GISA M1V16 were examined for their ability to (i) adhere to fibrinogen and fibronectin in vitro, (ii) persist in the bloodstream after intravenous inoculation, (iii) colonize aortic vegetations in rats, and (iv) compete for valve colonization by co-inoculation. Both GISA M1V16 and M1V2 adhered similarly to fibrinogen and fibronectin in vitro. In rats, GISA M1V16 was cleared faster from the blood (P < 0.05) and required 100-times more bacteria than parent M1V2 (10(6) versus 10(4)CFU) to infect 90% of vegetations. GISA M1V16 also had 100 to 1000-times lower bacterial densities in vegetations. Moreover, after co-inoculation with GISA M1V16 and M1V2Rif, a rifampin-resistant variant of M1V2 to discriminate them in organ cultures, GISA M1V16 was out-competed by the glycopeptide-susceptible counterpart. Thus, in rats with experimental endocarditis, GISA showed an attenuated virulence, likely due to a faster clearance from the blood and a reduced fitness in cardiac vegetations. The GISA phenotype appeared globally detrimental to infectivity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18930804     DOI: 10.1016/j.micpath.2008.09.003

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  12 in total

1.  Compensation of fitness costs and reversibility of antibiotic resistance mutations.

Authors:  Pia Schulz zur Wiesch; Jan Engelstädter; Sebastian Bonhoeffer
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

Review 2.  Interplay Between Antibiotic Resistance and Virulence During Disease Promoted by Multidrug-Resistant Bacteria.

Authors:  Edward Geisinger; Ralph R Isberg
Journal:  J Infect Dis       Date:  2017-02-15       Impact factor: 5.226

3.  VraR Binding to the Promoter Region of agr Inhibits Its Function in Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA.

Authors:  Yuanyuan Dai; Wenjiao Chang; Changcheng Zhao; Jing Peng; Liangfei Xu; Huaiwei Lu; Shusheng Zhou; Xiaoling Ma
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 4.  Mechanisms of vancomycin resistance in Staphylococcus aureus.

Authors:  Susana Gardete; Alexander Tomasz
Journal:  J Clin Invest       Date:  2014-07-01       Impact factor: 14.808

5.  Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300.

Authors:  Susana Gardete; Choonkeun Kim; Boris M Hartmann; Michael Mwangi; Christelle M Roux; Paul M Dunman; Henry F Chambers; Alexander Tomasz
Journal:  PLoS Pathog       Date:  2012-02-02       Impact factor: 6.823

Review 6.  Molecular Events for Promotion of Vancomycin Resistance in Vancomycin Intermediate Staphylococcus aureus.

Authors:  Qiwen Hu; Huagang Peng; Xiancai Rao
Journal:  Front Microbiol       Date:  2016-10-13       Impact factor: 5.640

7.  VraSR and Virulence Trait Modulation during Daptomycin Resistance in Methicillin-Resistant Staphylococcus aureus Infection.

Authors:  Agustina Taglialegna; Maria C Varela; Roberto R Rosato; Adriana E Rosato
Journal:  mSphere       Date:  2019-02-13       Impact factor: 4.389

8.  Importance of the collagen adhesin ace in pathogenesis and protection against Enterococcus faecalis experimental endocarditis.

Authors:  Kavindra V Singh; Sreedhar R Nallapareddy; Jouko Sillanpää; Barbara E Murray
Journal:  PLoS Pathog       Date:  2010-01-08       Impact factor: 6.823

9.  Spectrum of antibacterial activity and mode of action of a novel tris-stilbene bacteriostatic compound.

Authors:  Nikki Y T Man; Daniel R Knight; Scott G Stewart; Allan J McKinley; Thomas V Riley; Katherine A Hammer
Journal:  Sci Rep       Date:  2018-05-02       Impact factor: 4.379

10.  Comparative Analysis of Virulence and Toxin Expression of Vancomycin-Intermediate and Vancomycin-Sensitive Staphylococcus aureus Strains.

Authors:  Ye Jin; Xiao Yu; Shuntian Zhang; Xiaoyang Kong; Weiwei Chen; Qixia Luo; Beiwen Zheng; Yonghong Xiao
Journal:  Front Microbiol       Date:  2020-10-30       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.